NeOnc Technology Secures $16M PIPE Financing Led by Synctinive Capital

NeOnc Technology's PIPE Financing

• 💡 NeOnc Technology, a biopharmaceutical company focused on central nervous system cancers, has entered into a securities purchase agreement for a private placement in public equity (PIPE).
• 💰 The agreement is expected to generate up to $16 million in gross proceeds for the company.

Financing Details and Use of Funds

• 📈 The offering includes common stock and 5-year warrants, with a combined purchase price of $7.20 per share.
• 🛠️ Proceeds from the financing are intended for the repayment of debt, working capital, and general corporate purposes.

Lead Investor and Confidence

• 🏦 The PIPE financing is led by a $10 million investment from Synctinive Capital Management, a multistrategy investment firm.
• ✅ This significant investment signals institutional confidence in NeOnc's therapeutic pipeline and its long-term strategy.
• 🎤 Jane King reported on the announcement from the New York Stock Exchange for News Out.